ANNUAL GENERAL MEETING OF Q-MED AB (publ)

The Annual General Meeting of Q-Med AB (publ) was held on April 28, 2005 at 5 p.m. on Q-Med’s premises at Fyrisvallsgatan 7, Uppsala. Dividend The meeting decided that a dividend of SEK 8 per share shall be paid, of which SEK 3 comprises the regular dividend and SEK 5 an extra dividend. Board and fee The meeting decided, for the period up until the end of the next Annual General Meeting, to re-elect Göran Carstedt, Håkan Edström, Mikael Kamras, Anders Milton, Pia Rudengren, Åsa Rödén and Bengt Ågerup as members of the company Board. At the Board meeting following the Annual General Meeting Göran Carstedt was appointed Chairman of the Board. Furthermore, the meeting decided that Board fees of SEK 840,000 in total shall be paid for the period 2005/2006, comprising SEK 240,000 to the chairman of the Board and SEK 120,000 to each of the other members of the Board. Bengt Ågerup does not receive a Board fee. A fee shall be paid to the auditors in accordance with reasonable invoicing for the period up until the next Annual General Meeting. Nominations committee The Annual General Meeting decided that the nominations committee shall continue to consist of three members and elected Robert Wikholm as chairman (new election), with the assignment of finding, at the latest during the third quarter, two representatives from the major owners to be included in the nominations committee, and that a fee of SEK 60,000 be paid to the committee, to be allocated in accordance with the decision of the committee. This is an unchanged fee compared with the previous year. Incentives programme in Ixion Biotechnology, Inc. The proposal was approved. It was noted that the meeting expressed the opinion that incentives programs of this kind shall not be used for the remuneration of employees and members of the Board of Q-Med AB for work in subsidiary funds. Queries should be addressed to: Anne Rhenman, Director Investor Relations and Corporate Communications, Ph: +46(0) 70-974 90 15. Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA.